Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of LNZ101 and LNZ100 in Presbyopia
NCT05936489Phase 1Completed
- Sponsor
- LENZ Therapeutics
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aceclidine in presbyopia (2 arms), sponsored by LENZ Therapeutics. Primary endpoints: Maximum Plasma Concentration at Day 8, Time to Maximum Plasma Concentration at Day 8 and 3 more. Started Jul 2023; status: completed.
02
Drugs
aceclidine
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT05936489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05936489.